UNSPSC 51172127: Elziverine

This classification denotes an antispasmotic agent with the molecular formula C32H37N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1I2BO46745, chemically known as 6,7-dimethoxy-4-((4-(o-methoxyphenyl)-1-piperazinyl)methyl)-1-veratrylisoquinoline but generally known as elziverine, which bears US NIH Compound Identifier 65839. European Medicines Agency schedules Elziverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06498MIG.

UNSPSC 51172127 Elziverine is a Commodity code under which state and local governments procure pharmaceutical and laboratory products, including generic multi-source drugs, over-the-counter medications, and drug-testing supplies for corrections, health services, and pharmacy benefit programs. The issuing bodies span state health and human services agencies, county corrections departments, and multistate cooperative purchasing consortia. The scope of work includes specimen collection and drug testing services with laboratory certification requirements (SAMHSA, state DPS, or CAP accreditation); generic pharmaceutical procurement through authorized wholesalers with detailed product coding (NDC, SKU, UPC); and emerging programs such as direct-to-manufacturer prescription fulfillment models that bypass traditional pharmacy benefit managers and group purchasing organizations. Collin County Community Supervision and Corrections Department is a repeat recent buyer under this code, soliciting offender specimen collection and drug testing services with approximately 25,031 annual tests across five- and six-panel immunoassay screening and LC/MS/MS or GC/MS confirmation, as well as alternative testing methodologies including oral fluid and hair analysis.

Recent activity concentrates in Texas and Minnesota, with geographic participation extending to Oregon through cooperative purchasing vehicles. Collin County issued RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services with a response deadline of July 23, 2026 and estimated contract value of $600,000 over two years with optional three one-year renewals; evaluation weights understanding (30 points), firm qualifications (25 points), client references (15 points), and cost (30 points). The Minnesota Department of Administration's Office of State Procurement, administering the Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026; vendors must maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and comply with cGMP and DSCSA certification. The Texas Health and Human Services Commission posted an exploratory RFI (HHS0017013) on March 27, 2026, to solicit vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling emerging state interest in alternative pharmaceutical distribution models outside traditional PBM and GPO channels.